Anthony Wild

GE Healthcare AB wholesales and distributes pharmaceutical products. It promotes contrast agents for X-rays, magnetic resonance imaging, ultrasound and radiopharmaceuticals, use to predict and diagnose early-stage diseases. The company was founded on October 21, 1983 and is headquartered in Danderyd, Sweden.

MedTrace Pharma A/S provides medical devices for hospital departments. The firm developed several novel safety features, which combined will revolutionize blood flow imaging in PET. The company’s solution consists of a remote operated unit producing the radioactive water and two disposable kits, including a daily kit for production, and a patient kit for infusion. It aims to make radioactive water (O-15 H2O) practically available for clinical use allowing doctors to use the gold standard in the clinic. The company is headquartered in Vedbaek, Denmark.

The Swedish company was founded by Sture Lindegren, Milton Lönnroth, and Emma Aneheim, with Milton Lönnroth serving as CEO since incorporation.

Celcibus AB manufactures hydrogen fuel cells. The company is based in Västra Frölunda, Sweden. The Swedish company was founded by Anders Palmqvist, Lisa Palmqvist. The CEO is Philip Gillgard.

Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway.